Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01740726 · ClinicalTrials.gov registry record · NA
Comparison of Behavioral Activation and Antidepressant Medication in the Treatment of Adolescents With Depression
A NA study, sponsored by Emory University.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT01740726: Clinical Trial NA study, sponsored by Emory University.
NCT01740726 is a NA study that was terminated before completion, run by Emory University. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01740726, a NA study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study focuses on treating adolescents with depression. The study has two main purposes. The first is to compare a new form of therapy for depression called Behavioral Activation (BA) to the antidepressant medication fluoxetine. BA therapy helps depressed people get more involved in activities they find enjoyable, which can reduce symptoms of depression. Research shows that both BA and fluoxetine work to reduce depressive symptoms in adolescents. However, unlike previous research, this study examines how well the two treatment options work in comparison to each other. Participants in the study are randomized to receive treatment with either BA or fluoxetine for 18 weeks. The second aim of the study is to examine the brain functions of adolescents in both treatment groups. Participants undergo functional Magnetic Resonance Imaging (fMRI) scans before and after treatment. The data from these scans will be used to compare the brains of participants in the BA condition with those in the fluoxetine condition. Also, the scans may show possible differences between participants' brains before and after treatment. These data may help scientists determine the ideal form of depression treatment for different types of people.
Primary Outcome
Self-report measure, completed by the child, that assesses depressive symptom severity. The BDI-II total score ranges from 0 to 63, with a higher score indicating a higher level of depression. Change is the difference between the 42 week score and the baseline score.
Interventions
- DRUG Fluoxetine
- BEHAVIORAL Behavioral Activation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-03 |
| Phase | NA |
Why NCT01740726 stopped before completion
NCT01740726 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Fluoxetine is the first listed.
NCT01740726 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01740726 about?
NCT01740726 is a clinical study titled "Comparison of Behavioral Activation and Antidepressant Medication in the Treatment of Adolescents With Depression". This study focuses on treating adolescents with depression. The study has two main purposes. The first is to compare a new form of therapy for depression called Behavioral Activation (BA) to the antidepressant medication fluoxetine. BA therapy helps depressed people get more involved in activities t...
What is the current status of trial NCT01740726?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2013-01. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01740726?
The interventions under investigation include: Fluoxetine (DRUG), Behavioral Activation (BEHAVIORAL).
Who is sponsoring clinical trial NCT01740726?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01740726's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia